Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study (NCT04739072)
Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)
🩺 Plain-English Summary (8th-Grade Level)
This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.
Who can join: Review the eligibility criteria below.
Location: Banner - MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
- Biospecimen Collection (PROCEDURE)
- Electronic Health Record Review (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- Banner - MD Anderson Cancer Center — Gilbert, Arizona
- Baptist- MD Anderson Cancer Center — Jacksonville, Florida
- The Queen's Medical Center — Honolulu, Hawaii
- St. Luke's Cancer Institute — Boise, Idaho
- Cooper Hospital UNIV MED CTR. — Camden, New Jersey
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- Houston Methodist Cancer Center — Houston, Texas
- M D Anderson Cancer Center — Houston, Texas
- UT Health San Antonio MD Anderson Cancer Center — San Antonio, Texas
- Baylor Scott & White Research Institute — Temple, Texas
📞 Contact the Study Coordinator
Phone: (713) 792-2828
Email: adasari@mdanderson.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colorectal Adenocarcinoma
- Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases — St Louis, Missouri
- Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer — Birmingham, Alabama
- TAS102 in Combination With NAL-IRI in Advanced GI Cancers — Atlanta, Georgia
- Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer — Aurora, Colorado
- Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer — Los Angeles, California
Explore by condition: All Colorectal Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.